Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Energy Select Sector SPDR Fund — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Energy Select Sector SPDR Fund trades at $61.06. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | XLE | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $62.57 |
52-Week Low | $205.48 | $42.33 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
XLE trades at $61.03, up 1.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights a 40.52% 12-month rally driven by strong oil prices and geopolitical tensions, though Seeking Alpha rates it HOLD due to less attractive entry points. The ETF's performance is heavily influenced by top holdings like ExxonMobil and Chevron, which reported surging Q2 profits.
Outlook remains tied to oil price volatility and Middle East tensions, offering growth potential but with high sensitivity to supply disruptions. Risks include geopolitical instability and concentrated exposure to a few large-cap energy stocks, warranting caution despite bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
